Halperin DM - Search Results

1

Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma.

Raghav K, Liu S, Overman MJ, Willett AF, Knafl M, Fu SC, Malpica A, Prasad S, Royal RE, Scally CP, Mansfield PF, Wistuba II, Futreal AP, Maru DM, Solis Soto LM, Parra Cuentas ER, Chen H, Villalobos P, Verma A, Mahvash A, Hwu P, Cortazar P, McKenna E, Yun C, Dervin S, Schulze K, Darbonne WC, Morani AC, Kopetz S, Fournier KF, Woodman SE, Yao JC, Varadhachary GR, Halperin DM. Raghav K, et al. Among authors: halperin dm. Cancer Discov. 2021 Nov;11(11):2738-2747. doi: 10.1158/2159-8290.CD-21-0331. Epub 2021 Jul 14. Cancer Discov. 2021. PMID: 34261675 Free PMC article.

2

Resectable, borderline resectable, and locally advanced pancreatic cancer: what does it matter?

Halperin DM, Varadhachary GR. Halperin DM, et al. Curr Oncol Rep. 2014 Feb;16(2):366. doi: 10.1007/s11912-013-0366-9. Curr Oncol Rep. 2014. PMID: 24445498 Review.

3

A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers.

Halperin DM, Phan AT, Hoff AO, Aaron M, Yao JC, Hoff PM. Halperin DM, et al. BMC Cancer. 2014 Aug 2;14:561. doi: 10.1186/1471-2407-14-561. BMC Cancer. 2014. PMID: 25086465 Free PMC article. Clinical Trial.

4

A tale of two tumors: treating pancreatic and extrapancreatic neuroendocrine tumors.

Halperin DM, Kulke MH, Yao JC. Halperin DM, et al. Annu Rev Med. 2015;66:1-16. doi: 10.1146/annurev-med-061813-012908. Epub 2014 Oct 17. Annu Rev Med. 2015. PMID: 25341008 Review.

5

Phase I study of the anti-IGF1R antibody cixutumumab with everolimus and octreotide in advanced well-differentiated neuroendocrine tumors.

Dasari A, Phan A, Gupta S, Rashid A, Yeung SC, Hess K, Chen H, Tarco E, Chen H, Wei C, Anh-Do K, Halperin D, Meric-Bernstam F, Yao J. Dasari A, et al. Endocr Relat Cancer. 2015 Jun;22(3):431-41. doi: 10.1530/ERC-15-0002. Epub 2015 Apr 21. Endocr Relat Cancer. 2015. PMID: 25900182 Free PMC article. Clinical Trial.

6

Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study.

Phan AT, Halperin DM, Chan JA, Fogelman DR, Hess KR, Malinowski P, Regan E, Ng CS, Yao JC, Kulke MH. Phan AT, et al. Among authors: halperin dm. Lancet Oncol. 2015 Jun;16(6):695-703. doi: 10.1016/S1470-2045(15)70136-1. Epub 2015 May 5. Lancet Oncol. 2015. PMID: 25956795 Free PMC article. Clinical Trial.

7

Rational Clinical Experiment: Assessing Prior Probability and Its Impact on the Success of Phase II Clinical Trials.

Halperin DM, Lee JJ, Dagohoy CG, Yao JC. Halperin DM, et al. J Clin Oncol. 2015 Sep 10;33(26):2914-9. doi: 10.1200/JCO.2015.61.4362. Epub 2015 Aug 10. J Clin Oncol. 2015. PMID: 26261263 Free PMC article.

8

Clinical Trial Design in Neuroendocrine Tumors.

Halperin DM, Yao JC. Halperin DM, et al. Hematol Oncol Clin North Am. 2016 Feb;30(1):209-17. doi: 10.1016/j.hoc.2015.09.011. Hematol Oncol Clin North Am. 2016. PMID: 26614378 Review.

9

[177Lu-DOTA0,Tyr3]-octreotate in the treatment of midgut neuroendocrine tumors.

Halperin DM, Dasari A, Yao JC. Halperin DM, et al. Future Oncol. 2016 Feb;12(3):313-21. doi: 10.2217/fon.15.321. Epub 2016 Jan 13. Future Oncol. 2016. PMID: 26759064 Free PMC article. Review.

10

Future Directions in the Biology of Neuroendocrine Tumors.

Halperin DM, Dasari A, Yao JC. Halperin DM, et al. Pancreas. 2016 Jul;45(6):783-5. doi: 10.1097/MPA.0000000000000669. Pancreas. 2016. PMID: 27295529

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

105 results

Search Page

Filters